Zymeworks (ZYME) has disclosed a new risk, in the Costs category.
Zymeworks may face financial strain due to the costs and complexities following its transition to a Delaware corporation. The company’s decision to not proceed with certain Post-Arrangement Transactions, as originally planned, due to potential negative tax consequences could lead to operational and tax inefficiencies in its current structure. Furthermore, substantial non-recurring expenses incurred during the Redomicile Transactions may not be quickly recouped, posing a risk to Zymeworks’ short-term financial health and its ability to achieve the anticipated benefits of its corporate reorganization.
Overall, Wall Street has a Moderate Buy consensus rating on ZYME stock based on 2 Buys and 1 Hold.
To learn more about Zymeworks’ risk factors, click here.
